Abstract
Bi-allelic variants in XPNPEP3 are known to cause nephronophthisis-like nephropathy-1. However, recent findings indicate XPNPEP3 deficiency causes a broader phenotypic spectrum encompassing extra-renal manifestations. XPNPEP3 is suggested to be the human ortholog of ICP55, a mitochondrial protein involved in the processing and maturation of mitochondrial proteins in plants and yeast.
Here, we present a family with two children affected by a homozygous splice variant in XPNPEP3. Both children exhibited early-onset renal insufficiency and progressive mixed hypertrophic and dilated cardiomyopathy, requiring cardiac transplantation during childhood. RNA and protein analysis of patient fibroblasts and cardiac tissue revealed loss of XPNPEP3 expression due to the splice variant. Assessment of explanted cardiac tissue confirmed mitochondrial dysfunction, indicated by decreased cytochrome c oxidase activity and changes in mitochondrial morphology.
Although the deficiency of Xpnpep3 in zebrafish did not result in noticeable phenotypic abnormalities during early larval stages, transcriptomic and proteomic analyses revealed mitochondrial alterations. Notably, proteomic profiling identified decreased abundance of mitochondrial proteins in xpnpep3Δ7/Δ7 mutants as compared to wild-types, including those identified in our study as putative substrates of Xpnpep3. We hypothesize that impaired processing of these proteins plays a critical role in the early developmental molecular changes observed, potentially predisposing to disease and also underlies the clinical manifestations in affected children.
In summary, our study underscores that loss of XPNPEP3 causes a mitochondrial disorder with varied phenotypes, including cardiomyopathy, through a molecular mechanism likely involving abnormal processing and stabilization of mitochondrial precursor proteins. Adding XPNPEP3 to cardiac and mitochondrial disease gene panels is essential for the accurate diagnosis and management of potential cardiac complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Dutch Heart Foundation (grant number 03-003-2020-T062 awarded to Judith M.A. Verhagen).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical ethics Committee of the Erasmus MC (MEC-2021-0329). Written informed consent for genetic testing and publication of anonymized data were obtained from the subjects and their legal guardians.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data produced in the present study are available upon reasonable request to the authors.
